Tight Junction Protein 1 May Identify Sensitivity to Proteasome Inhibitors in Patients With Multiple Myeloma

A gene known as TJP1 (tight junction protein 1) could help determine which multiple myeloma patients would best benefit from proteasome inhibitors such as bortezomib, as well as combination approaches to enhance proteasome inhibitor sensitivity, according to a study led by researchers from The University of Texas MD Anderson Cancer Center. 

 The ASCO Post